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Abstract: Clinicians involved in the care of patients with cardiovascular conditions have
recently been confronted with an important body of literature linking inflammation and
cardiovascular disease. Indeed, the level of systemic inflammation as measured by circulating
levels of C-reactive protein (CRP) has been linked to prognosis in patients with atherosclerotic
disease, congestive heart failure, atrial fibrillation, myocarditis, aortic valve disease and heart
transplantation. In addition, a number of basic science reports suggest an active role for CRP
in the pathophysiology of cardiovascular diseases. This article explores the potential role of
CRP in disease initiation, progression, and clinical manifestations and reviews its role in the
prediction of future events in clinical practice. Therapeutic interventions to decrease circulating
levels of CRP are also reviewed.
Keywords: C-reactive protein, inflammation, atherosclerosis, risk prediction, cardiovascular
disease, acute coronary syndrome
Introduction
Cardiovascular disease is one of the leading causes of death worldwide and accounts
for 40% of all deaths in the US. Understanding the underlying basic biologic principles
and prognostic risk factors is fundamental to identifying the most appropriate
therapeutic strategies. Clinicians involved in the care of patients with cardiovascular
conditions have recently been confronted with an important body of literature linking
inflammation and cardiovascular disease. Indeed, the level of systemic inflammation
as measured by circulating levels of high sensitivity C-Reactive protein (hs-CRP)
has been linked to prognosis in patients with atherosclerotic disease, congestive heart
failure (CHF), atrial fibrillation (AF), myocarditis, aortic valve disease, and heart
transplantation. In addition, a number of basic science reports suggest an active role
for CRP in the pathophysiology of cardiovascular diseases. This article reviews the
underlying mechanisms by which CRP potentially participates in disease initiation,
progression, and clinical manifestations, and reviews its role as a predictor of future
clinical events. Therapeutic strategies to decrease CRP are reviewed.
C-reactive protein and atherosclerosis/
atherothrombosis
Atherosclerosis initiation and progression
Atherogenesis begins with endothelial dysfunction in response to various injuries
(L’Allier 2004). Central to this disease process are circulating low density lipoprotein
(LDL) molecules which transmigrate across the endothelium and are oxidized by
local reactive oxygen species (ROS). Oxidized LDL (Ox-LDL) molecules (and not
native, unmodified LDLs) possess direct cytotoxicity and stimulate endothelial cells
to express adhesion molecules that allow white blood cells to abnormally adhere to
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the endothelium and to differentiate into macrophages.
Macrophages express scavenger receptors on their surface
allowing unopposed phagocytosis of Ox-LDLs, leading to
the well known cytopathological designation of “foam
cells”. These foam cells are very active biologically and
secrete a host of chemotactic factors and cytokines
promoting smooth muscle cell activation/migration, cellular
apoptosis, and vascular inflammation. The known
“classical” risk factors associated with atherosclerosis –
dyslipidemia, diabetes, smoking, and hypertension – create
an environment of increased oxidative stress through
formation of ROS (Tardif et al 2003). Elevated levels of
ROS then activate redox-sensitive signaling pathways and
transcriptional factors in the cell nucleus such as nuclear
factor kappa B (NF-κB), peroxisome proliferator-activated
receptors (PPARs), and activator protein-1 (AP-1). Once
activated, transcriptional factors preferentially promote the
transcription of “atherogenic genes” that subsequently
express a host of proinflammatory factors, including
cytokines, chemokines, and adhesion molecules that are
responsible for endothelial activation, vascular dysfunction,
and inflammation.
Key inflammatory mediators believed to be involved in
atherosclerotic disease initiation and progression include
vascular-cell adhesion molecule-1 (VCAM-1), monocyte
chemotactic protein-1 (MCP-1), CD40 ligand, and CRP.
CRP is particularly interesting to study in the clinical setting
because of its biological properties that allow easy and
reliable measurements. The preferred methods of CRP
measurement today are high-sensitivity nephelometric
assays that can be performed on fresh, stored, and frozen
plasma (ex. Dade Behring BN II [Deerfield, IL, USA],
Abbott IMx [Abbott Park, IL, USA], Diagnostic Products
Corporation IMMULITE [Los Angeles, CA, USA], and
Beckman Coulter IMMAGE [Fullerton, CA, USA])
(Roberts et al 2000). These assays allow discrimination
within what was previously recognized as the normal range
(levels of CRP as low as 0.15 mg/L can now be measured,
corresponding to <2.5 percentile of the general population)
(Ledue et al 1998; Kapyaho et al 1989). Indeed, this
discrimination appears to be crucial in the realm of
cardiovascular diseases since most patients fall within the
“normal” range (<5.0 mg/L) of previous assays.
CRP was originally isolated as a protein that binds to
the C-polysaccharide of the cell wall of pneumococci. It is
a major acute phase reactant produced mainly by hepatocytes
after stimulation by cytokines, of which interleukin-6 (IL-
6) appears the major inducer. It is part of the so-called innate
immunity system. CRP levels increase six hours after acute
stimuli, reaching a peak within 48 hours (up to 100-fold)
(Kushner 1990). With abrupt cessation of stimuli, values
decrease exponentially at a rate close to the half-life of CRP
(18–20 hours) (Ridker 2003). Early reports showed no
diurnal variation and no age or gender dependence (Meier-
Ewert et al 2001; Imhof et al 2003; Rifai and Ridker 2003).
However, these reports were based on comparisons of CRP
levels across dissimilar studies with heterogeneous
populations. A recent large scale cohort study included 2749
white and black subjects aged 30 to 65 participating in the
Dallas Heart Study compared levels of CRP between
different race and gender groups. After adjustment for
traditional risk factors, body mass index, estrogen, and statin
use, a CRP level >3 mg/L was more common in white
women (odds ratio [OR] 1.6; 95% confidence interval [CI]
1.1 to 2.5) and black women (OR 1.7; 95% CI 1.2 to 2.6),
but not in black men (OR, 1.3; 95% CI, 0.8 to 1.9) when
compared with white men (Khera et al 2005).
CRP appears to play an active role in endothelial
dysfunction and atherosclerotic plaque formation and
progression and has been found within atherosclerotic
plaques (Figure 1). Indeed, CRP down-regulates endothelial
nitric oxide (NO) synthase (eNOS) transcription in
endothelial cells (EC) and destabilizes eNOS mRNA,
resulting in decreased NO release (Verma, Wang, et al 2002).
This inhibition of NO production facilitates endothelial cell
apoptosis and blocks angiogenesis (Verma, Szmitko, et al
2004). Among other proatherogenic effects, CRP
upregulates adhesion molecules (intercellular adhesion
molecule-1 (ICAM-1), VCAM-1, and E-selectin through
up-regulation of NF-κB involved in the nuclear transcription
of several proatherosclerotic genes (Pasceri et al 2000;
Verma et al 2003) and can facilitate leukocyte transmigration
by stimulating the release of MCP-1 (Pasceri et al 2001). It
also up-regulates angiotensin type-1 receptor (AT-1) in
vascular smooth muscle cells and stimulates migration,
proliferation, neointimal formation, and ROS production
(Pasceri et al 2000). In addition, CRP inhibits bone marrow-
derived endothelial progenitor cell survival and
differentiation, impairing maintenance of vascular integrity
(Verma, Kuliszewski, et al 2004; Verma, Szmitko, et al
2004).
Another mechanism by which CRP actively participates
in atheroma formation is facilitation of LDL uptake by
macrophages by opsonization, leading to foam-cell
formation (Zwaka et al 2001). Furthermore, CRP activates
complement (particularly C3) (Wolbink et al 1996), whichVascular Health and Risk Management 2006:2(3) 223
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has been found within atherosclerotic lesions and is believed
to be implicated in both the initiation and progression of
atherosclerosis (Niculescu and Rus 1999). CRP may also
induce the production of endothelin-1 (ET-1), a potent
endogenous vasoconstrictors and mediator of endothelial
dysfunction, leukocyte and platelet activation and cellular
proliferation (Miyauchi and Masaki 1999). Finally, CRP
stimulates the production of IL-6 in the vasculature (Yudkin
et al 2000). This finding is particularly important since IL-
6 is involved in a positive feedback loop to stimulate CRP
production by the liver.
Interestingly, Verma and colleagues recently suggested
that CRP may require dissociation from a pentameric to a
monomeric form (mCRP) to exert its proatherosclerotic
effects and that agents interfering with the conversion of
pentameric CRP to the more active monomeric form may
serve to limit CRP’s proinflammatory effects (Verma,
Kuliszewski, et al 2004). These findings were also confirmed
by Khreiss et al (2004). mCRP was able to increase
expression of adhesion molecules E-selectin, ICAM-1, and
VCAM-1 by human coronary artery endothelial cells
(HCAECs) as early as 4 hours after incubation. The increase
of expression was associated with increased adhesion of
neutrophils to HCAECs cultured with mCRP. Unlike mCRP,
the induction with the native pentameric CRP didn’t become
evident until 6 to 12 hours of incubation with a maximal at
24 hours, coincident with its dissociation time. These
findings support also the theory proposed by Verma and
colleagues that CRP requires dissociation to exert its full
proatherosclerotic effect (Verma, Szmitko, et al 2004).
Currently, there is no assay to measure mCRP specifically.
Therefore, it is plausible that CRP plays an active role
in disease initiation and progression by directly affecting
pro-atherogenic gene expression, pro-inflammatory
pathways and vascular homeostasis. Important results of a
post hoc analysis of the Reversal of Atherosclerosis with
Aggressive Lipid Lowering (REVERSAL) trial (n=502)
evaluating the impact of moderate versus intensive statin
therapy on atherosclerosis progression assessed by
intravascular ultrasound (IVUS) were recently reported
(Nissen et al 2005). The authors applied statistical methods
to examine the relationship between LDL-cholesterol (LDL-
Figure 1 CRP in the pathogenesis of atherosclerosis and atherothrombosis.
Abbreviations: AT-1, angiotensin-1; CRP, C-reactive protein; EC, endothelial cells; ET-1, endothelin-1; ICAM-1, intercellular adhesion molecule -1; IL, interleukin; LDL,
low-density lipoprotein; NO: nitric oxide; PAI-1, plasminogen activator inhibitor-1; TF, tissue factor;  VCAM-1, vascular cell adhesion molecule-1;  WBC: white blood cells.Vascular Health and Risk Management 2006:2(3) 224
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C) and CRP levels and between levels of both markers and
the rate of disease progression (by IVUS). They found a
significant relationship (although relatively weak) between
the reduction in LDL-C and the reduction in CRP levels in
the entire population (r=0.13, p=0.005). They also reported
that the reduced rate of progression seen with intensive (vs
moderate) treatment was significantly and independently
related to both greater reductions in atherogenic lipoprotein
and CRP levels. However, the correlation coefficients were
also relatively weak (and of similar magnitude) for both (r
values 0.11 and 0.14, respectively), suggesting that these
biomarkers account for only a small fraction of the overall
progression. Patients with reductions in both biomarkers
greater than the median had significantly slower progression
than those with smaller reductions (p=0.001). These findings
support the hypothesis that CRP level may eventually
become an interesting therapeutic target.
It is important to note that various other inflammatory
biomarkers such as IL-6, tumor necrosis factor-α (TNF-
α), ICAM-1, P-Selectin, E-Selectin, MCP-1, Il-1,
fibrinogen, and soluble CD40 ligand, have also been
shown to be independent predictors of cardiovascular risk
(Hwang et al 1997; Ridker, Buring, et al 1998; Harris et
al 1999; Ridker, Hennekens, et al 2000; Blake and Ridker
2001; Cipollone et al 2001; Heeschen et al 2003;
Kervinen et al 2004; L’Allier et al 2005). However, their
measurement is difficult in clinical practice because of
their short half-lives, lack of standardized assays, and
high cost.
Atherothrombosis
Numerous cohort studies link inflammation and thrombosis.
A postulated mechanism through which inflammation shifts
the hemostatic system in favor of thrombosis is the induction
of peripheral blood monocytes to synthesize tissue factor
by CRP (Cermak et al 1993). This finding appears
particularly important because tissue factor is a well-known
and potent stimulus for the extrinsic pathway of coagulation
and for endothelial cell activation and expression of adhesion
molecules in clinical atherothrombosis (Pasceri et al 2001).
Further in vitro studies revealed that incubation of human
aortic endothelial cells with CRP also resulted in a time-
and dose-dependent increase in secreted plasminogen
activator inhibitor-1 (PAI-1), PAI-1 activity, intracellular
PAI-1 protein, and PAI-1 mRNA. In addition, CRP was
shown to stabilize PAI-1 mRNA (Devaraj et al 2003).
Together with its role in endothelial dysfunction and
impaired homeostasis, these data support CRP’s active role
in clinical atherothrombosis in addition to its role in
atherosclerosis progression.
Prediction of future clinical events
(primary prevention)
Beyond its basic functions as an important inflammatory
biomarker and a proatherosclerotic/prothrombotic agent,
CRP has also been show to predict incidence of myocardial
infarction (MI), stroke, and sudden death. CRP emerged as
a potent risk marker of recurrent events among patients with
no or stable coronary artery disease (CAD), and those
undergoing coronary revascularization (Table 1). Many
large-scale epidemiological studies among apparently
healthy men and women have found CRP to be an
independent and strong predictor of future cardiovascular
risk (see Table 1 for relative risks and corresponding cutoff
values) (Kuller et al 1996; Ridker et al 1997; Tracy et al
1997; Ridker, Hennekens, et al 1998; Ridker, Cushman, et
al 1998; Ridker, Buring, et al 1998, 2001; Harris et al 1999;
Koenig et al 1999; Ridker, Rifai, et al 2000, 2001; Danesh
Table 1 Prognostic value of CRP in primary prevention
Study  n  Endpoint  Cutoff Risk
estimates
Ridker, Rifai, 28 Death/MI/ >8.5 mg/L vs RR=1.5
et al 2000 263 stroke/revasc <0.6 mg/L
Harris et al 1999 1293 Death ≥2.78 mg/L RR=1.6
Ridker et al 1997 543 MI ≥2.11 mg/L vs RR=2.9
≤0.55 mg/L
Ischemic ≥2.11 mg/L vs RR=1.9
stroke ≤0.55 mg/L
Tracy et al 1997 5201 MI >2.79 mg/L vs RR=2.67
<0.97 mg/L
Ridker, Hennekens, 122 Death/MI/ >7.3 mg/L vs RR=4.8
et al 1998 stroke/revasc <1.5 mg/L
MI/stroke >7.3 mg/L vs RR=7.3
<1.5 mg/L
Ridker, Glynn, 144 PAD 2.1 mg/L vs RR=2.1
et al 1998 0.55 mg/L
Koeing et al 1999 936 CV Death/MI 6.6 mg/L vs RR=2.4
0.4 mg/L
Danesh et al 2000 1531 CHD >2.4 mg/L vs RR=2.13
<0.9 mg/L





Danesh et al 2004 6428 CHD >2.0 mg/L vs RR=1.45
<0.78 mg/L
Abbreviations: CHD, coronary artery disease; CRP, C-reactive protein; CV
Death, fatal acute myocardial infarction or sudden death; MI, myocardial
infarction; Revasc, revascularization; RR, relative risk; PAD, peripheral arterial
disease.Vascular Health and Risk Management 2006:2(3) 225
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et al 2000; Mendall et al 2000; Roivainen et al 2000). This
finding was consistent across different subpopulations,
including elderly patients (Tracy et al 1997), smokers (Kuller
et al 1996), and post-menopausal woman (Ridker et al 1997;
Tracy et al 1997; Ridker, Hennekens, et al 1998; Ridker,
Rifai, et al 2000). Specifically, hs-CRP was the strongest
predictor of future vascular events when compared with
serum amyloid-A (SA-A), IL-6, ICAM-1, homocysteine,
lipoprotein (a), and LDL-C in the Women’s Health Study
(Liuzzo et al 1996; Ridker, Rifai, et al 2000). Furthermore,
an association between hs-CRP levels and all-cause
mortality has been demonstrated (Hwang et al 1997; Ridker,
Hennekens, et al 1998; Harris et al 1999). A practical
approach in the evaluation of the predictive value of CRP
has been to divide CRP levels into population-based
percentiles and quintiles: absolute hs-CRP values of 0.3 mg/
L, 0.6 mg/L, 1.5 mg/L, 3.5 mg/L, and 6.6 mg/L have been
reported as estimates of the 10th, 25th, 50th, 75th, and 90th
percentile cut-points for middle-aged Americans (Ridker et
al 2002). The proposed quintile cut-points are <0.5 mg/L,
0.5–1.0 mg/L, 1.0–2.0 mg/L, 2.0–4.0 mg/L, and >4.0 mg/L,
respectively (Ridker et al 1997, 2002; Ridker, Rifai, et al
2000; Ridker 2001b). The authors also proposed a simplified
approach using levels of <1 mg/L, 1–3 mg/L, and >3 mg/L
corresponding to low, moderate and high-risk groups,
respectively. It is suggested to repeat CRP test when CRP
levels are above 10 mg/L to exclude inflammatory diseases.
The risk of future cardiovascular events associated with each
quintile increment was 26% for men and 33% for women
after adjustment for age, smoking status, family history of
premature coronary disease, diabetes, hypertension,
hyperlipidemia, exercise level, and body-mass index
(Ridker, Buring, et al 2001). In addition and importantly,
CRP was found to enhance global coronary risk as assessed
by lipid-derived indices (such as LDL-C) and by the
Framingham Risk Score (FRS) that integrates age, lipid
profile, smoking status, blood pressure and diabetes (Ridker,
Cushman, et al 1998; Ridker, Rifai, et al 2000; Ridker 2001b;
Ridker, Buring, et al 2001; Ridker et al 2002). Indeed, hs-
CRP was shown to add prognostic information at all levels
of LDL-C and at all levels of FRS (Ridker et al 2002; Koeing
et al 2004).
Patients with elevated levels of both LDL-C and CRP
were shown to have almost 8 times the cardiovascular risk
of those with low levels of both markers. Moreover, it was
suggested that in the primary prevention setting, CRP is an
even stronger predictor of CV events than is LDL-C
(reduction of LDL-C to the lowest quintile would reduce
CV risk by 19% whereas CRP reduction to the lowest
quintile would theoretically afford a 40% reduction in CV
risk). Koenig et al (2004) confirmed that CRP enhances
global coronary risk as assessed by the FRS in a large cohort
of middle aged men from general population and the
contribution of CRP to coronary event risk was independent
of the FRS. The value of CRP levels in risk assessment might
be particularly high in the “low-and intermediate-risk”
subgroups identified by conventional methods of risk
detection.
However, the absolute value of CRP in the prediction of
CAD remains uncertain. Danesh et al (2004) published
results from a large prospective study on CAD (Reykjavik
Study) and a meta-analysis of 22 prospective studies to
evaluate the relevance of CRP and other inflammatory
markers in the prediction of CAD. After adjustment for
baseline values of established risk factors, the OR for CAD
was 1.45 (95% CI, 1.25–1.68) in a comparison of
participants in the top third of the group with respect to
baseline CRP values with those in the bottom third in the
Reykjavik Study. Similar overall findings were observed in
an updated meta-analysis involving a total of 7068 patients
with coronary heart disease. By comparison, the ORs in the
Reykjavik Study for coronary heart disease were generally
stronger for established risk factors, such as an increased
total cholesterol concentration (2.35) and cigarette smoking
(1.87). The authors therefore concluded that CRP is a
relatively modest predictor of coronary heart disease and
that recommendations regarding its use in predicting the
likelihood of coronary heart disease may need to be
reviewed. Of note, the independent relative risk associated
with increased CRP levels in this study appeared
considerably lower than in some earlier reports (Danesh et
al 2004). Furthermore, the investigators of the Dallas Heart
Study (n=3373) recently reported that CRP was a poor
predictor of atherosclerotic burden as assessed by coronary
calcium score (electron-beam computed tomography) and
aortic plaque (magnetic resonance imaging). In this study,
subjects with higher CRP levels had slightly more
subclinical atherosclerosis, but this association was not
independent of traditional cardiovascular risk factors
(Khera et al 2006).
Based on the available data and before the latter two
studies, the Center for Disease Control and the American
Heart Association suggested further clarification of the
predictive value of CRP in CAD in general population before
recommending its widespread use in clinical practice
(Pearson et al 2003).Vascular Health and Risk Management 2006:2(3) 226
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Prediction of future clinical events
(Acute coronary syndrome)
Accumulating data suggest that markers of inflammation
may be reliable markers of risk of CAD in the short- and
medium-term. This finding may be particularly pertinent
for acute coronary syndrome (ACS) (Table 2). Numerous
small studies showed a correlation between increasing levels
of CRP and risk of cardiac events in this clinical setting
(cardiac death, MI, recurrent angina, urgent
revascularization) (Liuzzo et al 1994; Morrow et al 1998;
Rebuzzi et al 1998; Verheggen et al 1999). The cutoff value
of CRP in those studies was variable and ranged between
3.0 mg/L and 15.5 mg/L. Overall, the results suggest that
elevated levels of baseline CRP are associated with increased
recurrent clinical events (such as death, MI,
revascularization, and refractory angina) within 14 days.
Bazzino et al (2001) showed that after a 90-day follow-up
period, an elevated CRP level at discharge appeared to be a
more sensitive (88% vs 47%) and specific (81% vs 70%)
marker of increased risk of future events than a positive
treadmill test. The negative predictive value was 98% for
CRP versus 90% for stress test. While two sub-analyses of
large multicenter trials involving ACS patients showed no
association between CRP levels at entry and risk of death
and MI during follow-up (Oltrona et al 1997; Montalescot
et al 1998), this was not the case in a Global Use of Strategies
To Open Occluded Coronary Arteries IV-Acute Coronary
Syndrome Trial (GUSTO IV-ACS) sub-analysis. Patients
participating in the GUSTO IV randomized trial not
undergoing early revascularization (n=7, 108) were included
in a dedicated post-hoc analysis to evaluate CRP and
Troponin T (TnT) as predictors of individual endpoints
(James et al 2003). Investigators reported that baseline levels
of TnT and hs-CRP were both independently related to 30-
day mortality and that the combination of both markers
provided a better stratification than either marker alone.
However, only TnT levels were related to 30-day MI. Along
the same line, Sabatine et al (2002) have proposed a
multimarker approach to stratification for ACS patients
using TnT, CRP, and B-Type Natriuretic Peptide (BNP).
Currently, CRP is recognized as a useful adjunct to standard
risk stratification in patients with ACS. The bulk of evidence
suggests that the predictive value of CRP is independent of
and additive to the predictive value of troponin levels.
However, there are currently no definitive data to support
the concept of tailoring therapy according to CRP levels to
decrease clinical events.
Beside its potential role in predicting short-term
prognosis and recurrent clinical events in patients with ACS,
CRP may also have a role in medium-term prognosis (5–37
months). The results of numerous large-scale studies are
concordant (Haverkate et al 1997; Toss et al 1997; Biasucci
et al 1999; Ferreiros et al 1999; Lindahl et al 2000; Heeschen
et al 2000; Muller et al 2002). The relative risk of meaningful
clinical events (such as death, MI, angina) in patients with
highest levels of baseline CRP varied between 2.0 and 4.1
(cutoff CRP values of 3.0–10.0 mg/L) (Table 2). Persistently
elevated CRP levels for >3 months after waning of
symptoms are also associated with increased risk of cardiac
events (Bazzino et al 2001). The Fragmin during Instability
in Coronary Artery Disease (FRISC) investigators showed
that the risk associated with elevated CRP levels at the time
index event continues to increase for several years (Lindahl
et al 2000). Despite these concordant results, it is worth
mentioning that other well designed studies showed that
high CRP level measured at 72 hours did not predict adverse
outcome in patients hospitalized for unstable angina (Oltrona
et al 1997). The best evidence to date comes from an analysis
of the Pravastatin and Atorvastatin Evaluation and Infection
Table 2 Prognostic value of CRP in acute coronary syndromes
Study  n  Endpoint  Cutoff Risk
estimates
Short term
Liuzzo et al 1994 31 Death/MI/urg. 3.0 mg/L RR=2.6
revasc
Morrow et al 1998 437 Death 15.5 mg/L RR=16.1
Rebuzzi et al 1998 102 MI 3 mg/L RR=6.0
Verheggen 211 Refractory angina 6 mg/L OR=2.19
et al 1999
Oltrona et al 1997 140 Death/MI/revasc 10 mg/L p=ns
Montalescot 68 Death/MI/angina/ 5 mg/L p=ns
et al 1998 revasc
Mid term
Ridker et al 2005 3,745 Death/MI 2 mg/L RR=1.4
Muller et al 2002 1,042 Death 10 mg/L OR=4.1
Heeschen 447 Death/MI 10 mg/L RR=2.0
et al 2000
Lindhal et al 2000 917 Death 10 mg/L RR=2.6
Ferreiros 194 Death/MI/ 15 mg/L HR=3.16
et al 1999 refractory angina
Biasucci et al 1999 53 UA 3 mg/L OR=8.6
Toss et al 1997 965 Death/MI >10 mg/L RR=3.5
vs
<2.0 mg/L
Haverkate 2,121 Sudden death/MI 3.6 mg/L RR=2.0
et al 1997
Abbreviations: CRP, C-reactive protein; HR, hazard ratio; MI, myocardial
infarction; Mid-term, in-hospital, 3–37 months; OR, odds ratio; RR, relative risk;
Short term, in-hospital, 3 months; UA, unstable angina; urg. revasc, urgent
revascularization.Vascular Health and Risk Management 2006:2(3) 227
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Therapy — Thrombolysis in Myocardial Infarction 22
(PROVE-IT TIMI 22) study (n=3745) evaluating the risk
of death from coronary causes and recurrent MI after an
ACS (Ridker at al 2005). The authors evaluated relationships
between LDL-C and CRP levels achieved on pravastatin
40 mg or atorvastatin 80 mg and clinical events during mean
follow-up of 24 months. They found a significant
relationship (although relatively weak) between the
reduction in LDL-C and that in CRP levels in the entire
population (r=0.16, p=0.001). Although the authors stated
that there was a completely independent linear relationship
between levels of LDL-C achieved after statin therapy and
events and CRP levels and events, the respective correlation
coefficients were not reported. While patients who achieved
LDL-levels lower than the median had lower event-rate than
those with higher levels (2.7 vs 4.0 events per 100 person-
years, p=0.008), an almost identical difference was observed
in patients who achieved CRP levels lower than the median
as compared with those with higher levels (2.8 vs 3.9 events
per 100 person-years, p=0.006). This effect was present at
all levels of LDL-C achieved. In addition, patients with both
low LDL-C and low CRP levels had significantly less events
(1.9 events per 100 person-years) than either patients with
high LDL-C and low CRP, low LDL-C and high CRP levels,
or high LDL-C and high CRP levels (respective hazard ratios
1.0, 1.3, 1.4, and 1.9, p<0.001). These observations led the
authors to conclude that patients who have low CRP levels
after statin therapy have better clinical outcomes than those
with higher levels, regardless of LDL-C levels achieved.
Strategies to reduce cardiovascular risk with statins might
eventually include CRP monitoring in addition to
cholesterol, since CRP levels were lower in the high-dose
statin group. Such results are concordant with those of
atherosclerosis progression studies (Nissen et al 2005) and
fuel the hypothesis that reducing inflammation in general
and perhaps CRP in particular may have a significant role
in controlling atherothrombosis and atherosclerosis
progression.
Prediction of future clinical events
(following revascularization procedures)
CRP predicts future clinical events after percutaneous
coronary interventions (PCI) (Table 3) and rises
proportionally to the instability of the culprit coronary
lesions (Tomoda and Aoki 2001). Furthermore, the pattern
of increase was correlated with restenosis. In patients with
stable CAD and subsequent restenosis, CRP increased up
to 96 hours of stent implantation, whereas in patients without
restenosis, CRP peaked at 48 hours then decreased. Patients
with angiographic evidence of restenosis at follow-up also
had significantly higher peak post-procedural CRP levels,
supporting the role of inflammation in restenosis after stent
implantation (Gottsauner-Wolf et al 2000). In addition,
higher levels of CRP were evident during follow-up of
patients with in-stent restenosis as compared with those
without, suggesting that inflammatory processes play an
important role in the occurrence of in-stent restenosis
(Angioi et al 2001). Similarly, in patients with stable angina
and one vessel disease who had stent placement,
normalization of hs-CRP levels within 72 hours after
coronary artery stenting identified a large subgroup of
patients who did not develop cardiovascular events during
a 12-month follow-up period (Gaspardone et al 1998). CRP
can also be a risk factor of stent thrombosis and recurrent
ischemic events after PCI. Chew et al (2001a) showed that
elevated baseline levels of CRP (>10.1 mg/L) were
associated with a 3.7-fold increase in the risk of death or
MI at 30 days after PCI, and that CRP is an independent
and additive factor to the increasing American College of
Cardiology/American Heart Association (ACC/AHA) lesion
score.
The association between systemic inflammation and
short-term adverse clinical outcome was not seen in patients
undergoing coronary bypass grafting (CABG). However
there is a significant increase in recurrent angina, MI, and
new revascularization procedures up to 6 years in patients
who had a high baseline CRP. No difference in cardiac and
total mortality was noted (Milazzo et al 1999). Further
studies are needed to assess more completely the impact of
higher levels of CRP on adverse clinical outcomes in patients
undergoing CABG.
Therefore, there is strong epidemiological and ex vivo
evidence that CRP plays an active role in atherosclerosis
initiation/progression and atherothrombosis. A definitive
causal relationship between CRP and clinical events is still
lacking in humans.
Table 3 Prognostic value of CRP after percutaneous coronary
intervention
Study n Endpoint Cutoff Risk
estimates
Heeschen et al 2000 447 Restenosis 10  mg/L RR=3.0
Muller et al 2002 1042 Death 10  mg/L OR=4.1
Chew et al 2001 727 Death/MI (30 days) 3.0  mg/L OR=3.68
Abbreviations: CRP, C-Reactive protein; MI, myocardial infarction; OR, odds
ratio; RR, risk ratio.Vascular Health and Risk Management 2006:2(3) 228
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C-reactive protein and other
cardiovascular conditions
Congestive heart failure
Patients with either ischemic or non-ischemic heart failure
show activation of proinflammatory cytokines possibly by
the activation of renin–angiotensin–aldosterone system and
the sympathetic nervous system (Ferrari et al 1995;
MacGowan et al 1997; Samsonov et al 1998). Elster et al
(1956) demonstrated that CRP was present in the serum of
thirty of forty patients manifesting CHF, independently of
age, sex or race. Higher CRP appeared to predict severity
of disease (Elster et al 1956) and CRP was more elevated in
patients with severe acute than those with severe chronic
heart failure. This finding, in conjunction with the tendency
of CRP level to drop with treatment, suggests that the
concentration of CRP is influenced by the severity of disease
(Pye et al 1990). Higher CRP levels were again observed in
patients with higher New York Heart Association (NYHA)
functional class and were related to higher rates of
readmission and mortality (Alonso-Martinez et al 2002).
To evaluate amino terminal-pro-BNP (NT-proBNP) and
CRP, separately and together, for assessment of risk of CHF,
Campbell et al (2005) performed a nested case-control study
of the 6105 participants of the Perindopril pROtection
aGainst REcurrent Stroke Study (PROGRESS), 258 subjects
who developed CHF resulting in death, hospitalization, or
withdrawal of randomized therapy during a mean follow-
up of 3.9 years were matched to one to three control subjects.
They found that NT-proBNP and CRP were independent
predictors of CHF risk after stroke or transient ischemic
attack (TIA). Moreover, NT-proBNP and CRP may be
markers of mechanisms of CHF pathogenesis distinct from
those responsive to angiotensin-converting enzyme
inhibitor-based therapy. While there appears to be a
correlation between CRP levels and prognosis, CRP’s
usefulness in predicting adverse outcomes in patients with
CHF beyond known predictors of adverse outcomes in this
patient population (such as left ventricular ejection fraction
[LVEF], functional class, markers of neurohumoral
activation, etc) remains to be proven.
Atrial fibrillation
A link between inflammation and AF has been proposed
based on post-operative histologic and genetic studies, and
the clinical association between AF and pericarditis.
Pathology studies support such a relationship in light of
inflammatory infiltrates, myocyte necrosis, and fibrosis on
atrial biopsies of patients with refractory arrhythmias. This
potential link was further established in a small case-control
study by Chung et al (2001) of patients with AF outside the
post-operative setting (n=202). They found elevated levels
of CRP in patients with AF as compared with those without
(21 mg/L vs 0.96 mg/L; p<0.001). The same group published
the results of a larger population-based cohort (n=5806;
median follow-up 7.8 years) assessing CRP as a predictor
of baseline and future development of AF (Aviles et al 2003).
In this study, baseline CRP predicted higher risk for
developing future AF (fourth vs first quartile adjusted hazard
ratio 1.31, 95% CI 1.08–1.58; p=0.005). Similar findings
were reported from an independent cohort study (n=2796;
OR of developing AF 1.19 per quartile of CRP) (Anderson
et al 2004). It remains uncertain whether AF triggers an
inflammatory response or baseline systemic inflammation
promotes AF. In addition, higher IL-6 and CRP levels were
found to be associated with higher fibrinogen and plasma
viscosity in patients with chronic AF, suggesting a link
between inflammation and prothombotic state in AF
(Conway et al 2004b, 2004c) as well as the surrogates of
thromboembolism as documented by transesophageal
echocardiography (left atrial thrombus, spontaneous echo
contrast, aortic atheroma, and low left atrial appendage shear
rate) (Conway et al 2004a; Thambidorai et al 2004).
Moreover, lower CRP levels have been shown to predict higher
conversion to sinus rhythm in patients with AF who undergo
direct current (DC) cardioversion, but failed to predict medium-
term outcome following cardioversion (Conway et al 2004a).
Although these studies showed a correlation between higher
CRP levels and the occurrence of AF and its thrombotic state,
further studies are needed to confirm a strong and direct causal
relationship between inflammation and subsequent
development of AF and its complications.
Aortic valve disease
Small pilot studies have tested the hypothesis of an
association between elevated CRP levels and aortic valve
Table 4 Reported independent prognostic value of CRP in
other clinical situations
Clinical situation  Event(s)
Atrial fibrillation AF development, LA thrombus, success of ECV
Myocarditis NYHA functional class, overall prognosis
Heart transplant Survival
vasculopathy
Aortic stenosis Disease progression
Abbreviations: AF, atrial fibrillation; CRP, C-reactive protein; LA, left atrium;
ECV, electrical cardioversion; NYHA, New York Heart Association.Vascular Health and Risk Management 2006:2(3) 229
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disease progression. Galante et al (2001) were among the
first investigators to demonstrate the association between
rate of progression of degenerative aortic valve disease and
elevated CRP levels, independent of the presence of
subclinical infection (H. pylori,  C. pneumonia).
Retrospective analyses showed that statin drugs exert a
beneficial effect on calcific aortic stenosis progression,
possibly through their antiinflammatory effect rather than
through their lipid lowering effects (Novaro et al 2001;
Bellamy et al 2002). In a small study, CRP levels decreased
after aortic valve replacement for non-rheumatic valve
stenosis (degenerative and bicuspid). However the decrease
in CRP was not substantial in all patients and all patients
did not have high CRP levels at baseline (Gerber et al 2003).
A recent randomized trial assigned 77 patients with calcific
aortic stenosis to treatment with high dose statins (a
treatment known to decrease CRP) and 78 to placebo. At
24 months follow-up, there was no significant difference in
the rate of progression of aortic stenosis. This finding was
similar regardless of the degree of the stenosis as assessed
by echocardiography and helical CT. Moreover there was
no relationship between LDL levels and the progression of
the disease (Cowell et al 2005).
Thus, large scale clinical trials with long-term follow-
up are needed to establish the role of CRP in aortic valve
stenosis progression.
Myocarditis
In lymphocytic myocarditis (LM) – the most common type
of myocarditis – an increase in CRP level correlates
positively with the NYHA functional class and inversely
with LVEF. Serum CRP levels were found to be significantly
higher in patients who die from LM within a 28-day period
of follow-up than in those who survive suggesting a
prognostic value for CRP in patients presenting with this
condition implying that the intensity of the inflammatory
reaction is of prognostic value (Kaneko et al 2000). Of note,
CRP levels measured in this setting are well above the ranges
assessed by hs-CRP assays.
Heart transplantation
CRP was shown to be higher in patients with advanced
stages of cardiac allograft vasculopathy disease (CAVD),
the major cause of death after transplantation. Eisenberg
et al (2000) demonstrated that hs-CRP might indeed be a
useful marker for survival after heart transplantation. In
a prospective study of 99 heart transplant recipients,
doubling of CRP baseline levels was independently
associated with an OR of 1.32 (p=0.025) of graft failure
during the 5.0±2.7-year follow-up. Furthermore,
Hognestad et al (2003) have reported a relationship
between CRP levels and development of transplant
allograft vasculopathy. Indeed, CRP increase during
follow-up was the only independent predictor for
transplant vasculopathy in their study. Prospective
treatment with pravastatin was associated with a 25%
reduction in CRP levels. In parallel, the use of statin drugs
were shown to decrease the incidence of severe cardiac
rejection accompanied by hemodynamic compromise,
improve the one-year survival, and reduce the incidence
of transplant vasculopathy (Kobashigawa et al 1995).
Therefore, these preliminary results are encouraging for
a role of CRP in the prediction of graft failure in heart
transplant recipients and in immunosuppression
monitoring.




Early evidence of a link between systemic inflammation
and cardiovascular events came from the Physician
Health Study. In this study, Ridker at al (1997) identified
543 apparently healthy men in whom acute MI, stroke,
or venous thrombosis subsequently developed and 543
participants who did not develop such complications and
measured baseline hs-CRP. Patients were randomly
assigned to receive aspirin or placebo. Baseline hs-CRP
was indeed higher in patients who went on to develop
MI or stroke. Interestingly, men with the highest initial
level of CRP (4th quartile) had the greatest benefit of
aspirin, with a relative MI risk reduction of 55.7% (risk
ratio [RR] 4.16 vs 1.80) as compared with 13.9%
reduction for those in the lowest quartile (RR 1.16 vs
1.00) (Ridker et al 1997). These results fuelled the
hypothesis that antiinflammatory agents (such as aspirin)
may have clinical benefits in preventing cardiovascular
disease. In a small case-control study of patients with
chronic stable angina (n=40), 300 mg of aspirin daily was
associated with a 29% decrease in CRP levels after six
weeks (Ikonomidis et al 1999). Furthermore, in a study
of consecutive patients (n=304) admitted for non-ST-
elevation ACS, those pretreated with aspirin tended to
have lower CRP and lower troponin I levels (Kennon etVascular Health and Risk Management 2006:2(3) 230
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al 2001). In this study, pretreatment with aspirin
neutralized the incremental risk of death/MI at 12 months
associated with high CRP levels, suggesting a role for
aspirin to decrease subclinical inflammation and an
additional mechanism through which aspirin can exert
its protective effect. However, subsequent dedicated trials
did not show convincing evidence that low-dose (75 mg–
325 mg) could lower circulating levels of hs-CRP (and
hence systemic inflammation) (Feng et al 2000; Feldman
et al 2001; Azar et al 2003) (Table 5). Therefore, low-
dose aspirin is not currently recognized as a potent
antiinflammatory agent and is believed to exert its
beneficial effect mainly through its anti-platelet function.
Investigators from the Cleveland Clinic Foundation
showed that pre-treatment with inhibitors of the P2Y12
adenosine receptor, such as clopidogrel, is associated with
a substantial reduction in 30-day death or MI in patients
with baseline CRP greater than 1.1 mg/dL undergoing PCI
and stenting (Chew et al 2001b). Furthermore,
periprocedural treatment with clopidogrel was associated
with an attenuation of the increase in CRP by up to 65%
(Vivekananthan et al 2004).
Statins
The primary mechanism of action of this class of drugs is
certainly inhibition of 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase with consequent
decrease in LDL-C. However, a non-lipid effect was first
noticed in the Cholesterol and Recurrent Events (CARE)
trial. In a post hoc study of 472 randomly selected
participants who remained free of recurrent coronary events
during five years follow-up (Ridker, Rifai, et al 1999), those
allocated to placebo experienced an increase in median CRP
level while those allocated to pravastatin experienced a
decrease in median CRP level (difference between groups,
−21.6%; p=0.007). Attempts to relate the magnitude of
change in CRP to the magnitude of change in lipids in both
the pravastatin and placebo groups did not reveal any
significant relationship. The authors concluded that these
data supported the potential for non-lipid effects of
pravastatin. Similar results were reported in the Myocardial
Ischemia Reduction with Acute Cholesterol Lowering
(MIRACL) study involving high-risk ACS patients (Kinlay
et al 2003). Patients randomized to high-dose atorvastatin
(vs placebo) experienced greater reductions in CRP (−83%
Table 5 Treatment effect on hs-CRP levels
 Study n Treatment Effect Clinical setting p value
Ridker, Hennekens, et al 1999 472 Pravastatin 40 mg ↓ 17.4% Secondary prevention 0.007
Placebo ↑ 4.2%
Kinlay et al 2003 2402 Atorvastatin 80 mg ↓ 83% Unstable <0.0001
Placebo ↓ 74%
Ridker et al 2005 3745 Atorvastatin 80 mg ↓ 89% Unstable <0.001
Pravastatin 40 mg ↓ 82%
Nissen et al 2005 502 Atorvastatin 80 mg ↓ 36% Stable and unstable <0.001
Pravastatin 40 mg ↓ 3%
Bogaty 2004 35 Rofecoxib 25 mg ↓ 59% Stable 0.03
Placebo ↑ 35%
Monakier 2004 34 Rofecoxib 25 mg ↓ 98% Unstable <0.02
Placebo ↑ 100%
Fliser 2004 199 Olmesartan 20 mg ↓ 15.1% Hypertension <0.05
Després et al 2005 1036 Rimonabant 20 mg ↓18% Overweight 0.020
Placebo ↓7.5%
Wannamethee et al 2002 3628 Physical activity ↓ 18% Stable (elderly men) 0.0005
Mattusch et al 1999 14 Endurance training ↓ 31% Healthy subjects <0.05
Chrysohoou et al 2004 3042 Mediterranean diet ↓ 20% Stable 0.015
Abbreviations: hs-CRP, high sensitivity C-reactive protein.Vascular Health and Risk Management 2006:2(3) 231
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vs −74%, p<0.001). Reductions in CRP were observed in
patients with baseline LDL-C <3.2 mmol/L and >3.2 mmol/
L and among all other important subgroups. By 16 weeks,
CRP was 34% lower with atorvastatin than with placebo.
In a small 22 patients study, treatment with simvastatin,
pravastatin, and atorvastatin produced similar significant
reduction of hs-CRP at six weeks (Jilal et al 2001). The
JUPITER trial is currently recruiting patients (objective
n=15000) with low LDL and high CRP to specifically test
the hypothesis that decreasing CRP with a statin drug
translates into clinical benefits (Ridker 2003a). Statins
therapy in patient undergoing PCI significantly decreased
the one year mortality and MI without affecting the need
for revascularization in patients with high baseline CRP
levels (Chan et al 2003).
Statins currently represent the most promising
cardiovascular drugs to reduce CRP in clinical practice. Two
recent large scale clinical trials have reported larger
reductions of hs-CRP levels with atorvastatin 80 mg as
compared with pravastatin 40 mg (Nissen et al 2005; Ridker
et al 2005).
Angiotensin-converting enzyme inhibitors and
receptor blockers
The impact of an angiotensin-converting enzyme (ACE)
inhibition on systemic inflammation has not been
completely documented. Early studies have suggested a
favorable effect. Data from a prospective study (n=507)
suggested that treatment with ACE inhibitors was
associated with lower (2.6-fold; p<0.0001) median CRP
levels in patients following stroke (Di Napoli and Papa
2003). However, treatment of high-risk patients with the
ACE inhibitor ramipril did not result in CRP reduction
in the Heart Outcomes Prevention Evaluation (HOPE)
study (Yusuf et al 2000). Investigators from other large-
scale clinical trials evaluating ACE inhibition in patients
with coronary atherosclerosis have not yet reported
significant benefits on CRP levels (Fox 2003; Braunwald
et al 2004). Definitive data in CAD patients are not
available and no conclusion can be drawn at this time,
although ACE inhibition is expected to have a modest
impact at best on CRP levels.
The EUropean Trial on Olmesartan and Pravastatin in
Inflammation and Atherosclerosis (EUTOPIA) investigators
found significant reduction (15.1%) in measured CRP levels
in hypertensive patients with microvascular inflammation
treated with the angiotensin receptor blocker olmesartan.
The reduction was present at six weeks (as compared with
baseline levels) while there was no significant change with
placebo (Fliser et al 2004).
Cannabinoid-1 receptor blockers
A recent randomized controlled trial (n=1036) showed that
the specific cannabinoid-1 receptor blocker rimonabant
reduces body weight and waist circumference and improves
the profile of several metabolic risk factors in overweight
or obese individual who have hyperlipidemia. Moreover,
plasma CRP levels decreased by 0.9 mg/L in the rimonabant
20 mg daily group as compared with 0.4 mg/L in the placebo
group (p=0.020) (Després et al 2005).
Hormone replacement therapy
Recent studies demonstrated that oral hormone replacement
therapy (HRT) causes a sustained increase in CRP. Indeed,
as compared with nonusers of HRT, median CRP levels were
higher among women using HRT preparations (Ridker,
Rifai, et al 1999). Furthermore, in a large-scale randomized
trial of HRT, post-menopausal hormones were found to
rapidly increase the concentration of CRP (approximately
2-fold), which may explain the early adverse effects of
estrogen therapy seen in this trial (Cushman et al 1999).
The addition of progesterone is associated with an
insignificant increase in CRP levels (Yildirir et al 2002).
Interestingly, droloxifene, a selective estrogen receptor
modulator (SERM), was found to have little or no
proinflammatory effects on CRP or IL-6 and had mixed
effects on endothelial adhesion molecules as compared with
estrogen therapy. These observations provide rationale for
continuing to evaluate the potential cardiovascular benefits
of SERM’s (Herrington et al 2002) and to limit the use of
HRT.
Cyclooxygenase-2 inhibitors
The case of cyclooxygenase-2 (COX-2) inhibitors is of
particular interest. Indeed, this class of drugs represents
potent antiinflammatory agents capable of rapidly and
decisively decreasing circulating CRP levels and systemic
inflammation through selective inhibition of COX-2. This
enzyme, along with cyclooxygenase-1 (COX-1), catalyzes
the transformation of the substrate arachidonic acid into
molecular entities that include thromboxane A2
(prothrombotic) and prostacyclin (antithrombotic). The
possibility of selectively inhibiting COX-2 generated the
hypothesis that inflammation could be effectively controlled
without the major adverse effect of COX-1 inhibition
(gastrointestinal bleeding). This therapeutic potentialVascular Health and Risk Management 2006:2(3) 232
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combined with the more widely accepted concept that
atherosclerosis is modulated by inflammation was enough
to generate enthusiasm for a new strategy to limit its
progression and clinical manifestations through chronic
COX-2 inhibition. Early randomized trials demonstrated that
COX-2 inhibitors could effectively reduce hs-CRP levels
in patients with ACS (Bogaty et al 2004; Monakier et al
2004). However, an unexpected problem was first noted in
the Vioxx Gastrointestinal Outcomes Research (VIGOR)
study (Mukherjee et al 2001). Patients treated with rofecoxib
(a COX-2 inhibitor) were found to have more MIs than
patients treated with naproxen (COX-1 inhibitor) in the
control group. More recent placebo controlled trials clearly
confirmed this toxicity (Bresalier et al 2005; Nussmeier et
al 2005; Solomon et al 2005). The most likely reason for
the increased atherothrombotic events is that COX-2
inhibitors, while reducing CRP levels, also reduce the
production of the antithrombotic substance prostacyclin
without changing the production of the prothrombotic
thromboxane A2 (McAdam et al 1999). These findings
illustrate that although vascular inflammation is a key factor
in atherosclerosis progression and clinical manifestations
and decreasing vascular inflammation to reduce events is
an appealing therapeutic strategy, the mechanisms of action
of antiinflammatory agents are extremely important and
caution should be exercised.
Non-pharmacologic interventions
Cardiac rehabilitation and exercise
training
Cardiac rehabilitation programs improve numerous cardiac
risk factors. The relationship between physical activity and
CRP levels was examined in many studies. Men enrolled in
the British Regional Heart Study (n=3810) were evaluated
by questionnaire to assess physical activity and provided a
fasting blood sample between 1998 and 2000
(approximately 20 years after enrolment). Physical activity
showed a significant and inverse dose-relationship with CRP
(increasing quartiles of physical activity: 1.73 mg/L,
1.73 mg/L, 1.57 mg/L, and 1.42 mg/L, p<0.0005)
(Wannamethee et al 2002). Similar findings were reported
from the Aerobics Center Longitudinal Study (Dallas, TX,
US) (Church et al 2002), and by Aronson et al (2004).
Interestingly, Mattusch et al (2000) reported that subjects
preparing for a marathon experienced a 31% decrease in
circulating hs-CRP levels (1.19 mg/L vs 0.82 mg/L, p<0.05).
Therefore, aerobic exercise training and improved
cardiorespiratory endurance are associated with reduced
CRP levels, suggesting that exercise training has
antiinflammatory effects. Regular physical exercise appears
important in a global therapeutic strategy designed to
decrease CRP in the high-risk patient population identified
by high level of circulating CRP.
Weight loss and diet
CRP levels are higher in obese subjects, particularly in those
with the metabolic syndrome. Indeed, CRP levels are related
to abdominal obesity and insulin-resistance (Visser et al
1999; Yudkin et al 1999). Adipocytes are known to secrete
IL-6 which increases the liver production of CRP. Thus,
one mechanism of reduction of cardiovascular risk by weight
loss may through a decrease in the major stimulus (IL-6)
for hepatic CRP production and consequent decrease in
CRP’s proatherogenic effects. Caloric restriction and weight
loss lowers IL-6 and CRP levels and may beneficially
suppress a chronic and systemic inflammatory response
(Heilbronn and Clifton 2002). Weight loss and diet are
intrinsically linked. The Mediterranean diet has been one
of the most thoroughly studied regimens with regard to its
impact on cardiovascular diseases (CVD) and it has been
shown to have a beneficial role by reducing BP, body mass
index, platelet aggregation, and other hematological factors.
Specifically, Chrysohoou et al (2004) recently demonstrate
that the Mediterranean diet was independently associated
with a reduction in various inflammatory and coagulation
markers related to CVD. Participants who were closer to
this diet had lower CRP, IL6, homocysteine, fibrinogen
levels, and white blood counts compared with those who
were away from this pattern diet. The authors concluded a
correlation between the beneficial actions of this diet on
the cardiovascular system. Reductions of CRP levels (40%
reduction at two years) were confirmed in other major trials
and adherence to this diet was also associated with a
significant reduction in metabolic syndrome (Esposito et al
2003). Furthermore, this diet has also been associated with
a reduction in all-cause mortality (Trichopoulou et al 2003;
Knoops et al 2004). Moderate alcohol consumption is also
associated with a decrease in CRP. The relationship between
alcohol consumption and CRP was specifically evaluated
in a cross-sectional survey and over time among 1732 men
and 1101 women participating in the Pravastatin
Inflammation/CRP Evaluation Study. CRP levels were lower
in those with moderate alcohol intake versus light or
occasional intake. In five categories of alcohol intake (no
alcohol or <one drink monthly, one to three drinks monthly,
one to four drinks weekly, five to seven drinks weekly, andVascular Health and Risk Management 2006:2(3) 233
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≥ or = two drinks daily), median CRP levels were 2.60 mg/
L, 2.20 mg/L, 1.70 mg/L, 1.60 mg/L, and 1.80 mg/L,
respectively (Albert et al 2003). In a cohort of well-
functioning men and women aged 70 to 79 years, Volpato
et al (2004) found that compared with subjects who
consumed one to seven drinks per week, those who never
drank had an increased likelihood of having high levels of
both IL-6 and CRP, as did those who drank eight or more
drinks per week. In this study and after adjustment for age,
race, smoking status, history of diabetes, history of
cardiovascular disease, physical activity, high-density
lipoprotein cholesterol, antiinflammatory medications,
statins, and total fat mass, alcohol intake showed a J-shaped
relationship with mean IL-6 (p for quadratic term <0.001)
and CRP (p=0.014) levels. Alcohol may therefore attenuate
cardiovascular mortality in part through an antiinflammatory
mechanism. These results might suggest an additional
biological explanation for the attenuation of cardiovascular
morbidity/mortality associated with moderate alcohol
consumption.
The inflammation hypothesis and C-
Reactive protein-guided therapy
In light of the intensive basic and clinical research in the
pathophysiology in CVD, arterial inflammation has
emerged as a new risk factor for the progression of
atherosclerosis and its associated clinical manifestations.
CRP was extensively investigated as a marker and
prognostic factor in epidemiologic studies and elevated
CRP levels predict worse outcomes even in apparently
healthy individuals as well as in patients with unstable
coronary syndromes. In a recent review, Bhatt and Topol
(2002) proposed a clinical trial design to evaluate the
practical utilization of CRP to allocate medical therapy.
This trial would test the “inflammation hypothesis” by
randomizing patients with a history of CVD to either
standard therapy or CRP-guided strategy. All patients
would receive aspirin. Statins would be prescribed per
protocol if LDLs were >100 mg/dL and ACE-I if LVEF
was decreased, respectively. Additional therapies would
be initiated and medications would be titrated according
to CRP levels in the CRP-guided arm (with the goal of
achieving optimal CRP levels in this group). This
“inflammation-guided” strategy would also include
deoxyribonucleic acid (DNA) analysis to ascertain the
relationship between polymorphisms of inflammatory
markers and drug interactions. Positive results would
validate this strategy, which could be easily implemented
by clinicians.
Conclusion
Atherosclerosis is a complex and systemic disease in which
vascular inflammation likely plays a key role. Indeed, there
is evidence that inflammation is closely linked to
atherosclerotic disease at all stages, from silent progression
to clinical manifestations. Experimental studies suggest that
CRP is an active player in the pathophysiology of
atherosclerosis. Moreover, there is strong epidemiologic
evidence that mediators of inflammation, especially hs-CRP,
predict cardiovascular risk independently of “classical” risk
factors. This finding is particularly pertinent when
considering that a significant proportion of CAD cases are
not associated with any prominent “classical” risk. Although
an elevated hs-CRP level is now clearly established as an
independent risk factor for CAD, the magnitude of the effect
remains the subject of heated debate and strong
recommendations for its use in clinical practice have not
been issued. Its impact may be particularly important in the
intermediate risk patients as assessed by conventional
methods. CRP levels also have important prognostic
implications in other cardiovascular diseases, such as CHF,
AF, aortic valve disease, myocarditis and heart
transplantation. A number of pharmacological and non-
pharmacological interventions have been shown to decrease
hs-CRP levels. Because most of these interventions have
other known beneficial effects, it is currently difficult to
independently assess the impact of hs-CRP reduction on
cardiovascular diseases. However, dedicated clinical trials
are ongoing and should provide important insight into the
“inflammatory-hypothesis”.
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